Q2 Earnings Estimate for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at HC Wainwright issued their Q2 2027 EPS estimates for shares of CG Oncology in a report issued on Friday, November 6th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.93) per share for the quarter. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.13) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2027 earnings at ($0.82) EPS.

A number of other analysts have also issued reports on the company. Truist Financial lifted their price target on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Guggenheim dropped their price target on CG Oncology from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Monday. Wedbush increased their price objective on CG Oncology from $80.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Thursday, October 15th. Finally, Royal Bank Of Canada decreased their price objective on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CG Oncology has an average rating of “Moderate Buy” and a consensus price target of $88.11.

CG Oncology Price Performance

Shares of CG Oncology stock opened at $72.64 on Monday. The business has a 50 day simple moving average of $68.19 and a two-hundred day simple moving average of $66.27. CG Oncology has a 12 month low of $35.80 and a 12 month high of $80.97. The stock has a market capitalization of $6.49 billion, a P/E ratio of -26.32 and a beta of 0.35.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CGON. Public Sector Pension Investment Board purchased a new position in CG Oncology during the third quarter worth approximately $12,902,000. Fisher Asset Management LLC grew its holdings in CG Oncology by 4.4% in the 3rd quarter. Fisher Asset Management LLC now owns 476,917 shares of the company’s stock valued at $33,809,000 after buying an additional 19,939 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of CG Oncology by 48.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 248,725 shares of the company’s stock worth $17,597,000 after acquiring an additional 81,296 shares during the last quarter. Jefferies Financial Group Inc. increased its stake in shares of CG Oncology by 8.5% in the 3rd quarter. Jefferies Financial Group Inc. now owns 835,342 shares of the company’s stock worth $59,217,000 after acquiring an additional 65,395 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC increased its stake in shares of CG Oncology by 6.3% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 22,186 shares of the company’s stock worth $1,573,000 after acquiring an additional 1,316 shares during the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director owned 1,000 shares of the company’s stock, valued at approximately $62,060. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 3,000 shares of company stock worth $209,580. 4.80% of the stock is currently owned by corporate insiders.

More CG Oncology News

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $100 price target. It raised its FY2026 EPS estimate to a loss of $2.94 per share from $3.60 and its Q4 2026 estimate to a loss of $0.70 from $1.03. HC Wainwright estimates
• Positive Sentiment: Guggenheim kept a Buy rating with an $89 target, while Wedbush raised its target to $84 and maintained an Outperform rating. Both targets are above the $72.64 reference price in the supplied reports. Guggenheim rating Wedbush rating
• Positive Sentiment: The company’s reported quarter beat estimates: EPS was a loss of $0.64 versus expectations of a $0.83 loss, and revenue was $1.60 million versus $0.55 million expected. What CG Oncology’s Third Quarter Earnings Means For Shareholders
• Neutral Sentiment: A short-interest report listed zero shares sold short and a zero-day days-to-cover ratio, indicating no reported short position that would clearly explain the move. The report’s wording about an increase conflicts with its zero-share figure.
• Negative Sentiment: HC Wainwright cut its FY2027 EPS estimate to a loss of $3.61 from $2.83, FY2028 to a loss of $1.33 from $0.65, and FY2030 profit estimate to $5.00 from $6.88. These revisions point to weaker longer-term expectations despite the firm’s Buy rating. HC Wainwright estimates

CG Oncology Company Profile

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.